Scientific Activity and Needs Among Medical Oncology Units in Sicily: A Survey of The Italian Association of Medical Oncology
Authors:
- R. BordonaroRBR. Bordonaro
- N. BorsellinoNBN. Borsellino
- A. ButeraABA. Butera
- M. CarusoMCM. Caruso
- F. FerraùFFF. Ferraù
- R. RusselloRRR. Russello
- G. SavioGSG. Savio
- R. ValenzaRVR. Valenza
- F. ZerilliFZF. Zerilli
- V. GebbiaVGV. Gebbia
- 1 February 2010
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 22 (1) , 48-53
Abstract
In the era of targeted therapies and combined modalities of treatment, scientific research plays a role of paramount importance in improving knowledge of cancer treatment. The aim of this survey was to review the scientific activity of medical oncology units in Sicily and to analyze their needs and possible pitfalls in order to improve future scientific cooperation. The regional section of the Italian Association of medical Oncology (AIOM) approved this survey in November, 2007. A systematic review of scientific activity produced by medical oncology units in Sicily during the last 5 years has been reviewed. Papers dealing with solid tumors reported in the pubmed web site have been included in the analysis. Data were reported as absolute number of published papers and impact factor per medical oncology unit and also as a ratio between global impact factor and the number of personnel working in each single unit to analyze scientific production according to the workforce of each institution. We identified a total of 283 papers reported in pubmed between 2004 and March, 2009. The mean number of publications/unit was 10.9 with a range of 0-50. The mean number of publications/year was 11.7 with a range of 0.2-10. The 15 units included in the impact factor evaluation published 252 papers with a total impact factor of 1014.6 points in 5 years with a mean of 63.4 points per institution and a mean of 4.02 points/paper. However only four medical oncology units reported a cumulative 5-year impact factor ≥100 points. This survey has shown that a minority of medical oncology units in Sicily is constantly involved in clinical research although at different levels of activity. Overall the percentage of patients enrolled in clinical trials is very low. The main reasons for lack of participation in clinical trials include insufficient medical personnel, the absence of a specifically dedicated research unit inside the medical oncology structures and in some cases lack of research experience and of specific interests in this field.Keywords
This publication has 13 references indexed in Scilit:
- Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)Clinical Breast Cancer, 2008
- Confronting Medical Errors in Oncology and Disclosing Them to Cancer PatientsJournal of Clinical Oncology, 2007
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004
- Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory ProcessDrug Information Journal, 2002
- Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”Journal of Clinical Epidemiology, 2001
- Long-term survival in Hodgkin's disease patientsEuropean Journal of Cancer, 2000
- The “inclusion benefit” in clinical trialsThe Journal of Pediatrics, 1999
- Evidence based medicine: what it is and what it isn'tBMJ, 1996
- Centralised treatment, entry to trials and survivalBritish Journal of Cancer, 1994
- Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trialsCancer, 1985